Artiva Biotherapeutics (NASDAQ:ARTV) Director Purchases $247,693.92 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. bought 24,944 shares of Artiva Biotherapeutics stock in a transaction on Friday, July 31st. The stock was purchased at an average price of $9.93 per share, for a total transaction of $247,693.92. Following the completion of the acquisition, the director owned 17,329,570 shares in the company, valued at $172,082,630.10. This represents a 0.14% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, July 29th, Ra Capital Management, L.P. purchased 20,824 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $9.99 per share, with a total value of $208,031.76.
• On Friday, July 24th, Ra Capital Management, L.P. acquired 41,319 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $9.99 per share, with a total value of $412,776.81.
• On Thursday, July 23rd, Ra Capital Management, L.P. acquired 59,880 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $9.96 per share, with a total value of $596,404.80.
• On Wednesday, July 22nd, Ra Capital Management, L.P. acquired 84,124 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $9.93 per share, for a total transaction of $835,351.32.
• On Tuesday, July 21st, Ra Capital Management, L.P. bought 120,582 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $9.55 per share, for a total transaction of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. bought 15,102 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.97 per share, for a total transaction of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. bought 6,552 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.94 per share, with a total value of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. purchased 1,876 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $8.98 per share, with a total value of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. purchased 31,000 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $8.88 per share, for a total transaction of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $8.89 per share, for a total transaction of $1,110,298.77.

Artiva Biotherapeutics Price Performance

ARTV stock opened at $10.10 on Monday. The stock has a market capitalization of $249.64 million, a price-to-earnings ratio of -2.85 and a beta of 2.18. Artiva Biotherapeutics, Inc. has a 52-week low of $2.22 and a 52-week high of $14.53. The stock’s fifty day simple moving average is $9.01 and its 200-day simple moving average is $7.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ARTV has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Wall Street Zen cut shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. HC Wainwright boosted their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $41.00 price target on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $39.00.

Institutional Investors Weigh In On Artiva Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth about $79,000. Qube Research & Technologies Ltd purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth about $58,000. Jane Street Group LLC purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth about $67,000. Bridgeway Capital Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth about $53,000. Finally, BNP Paribas Financial Markets increased its position in Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after purchasing an additional 117,733 shares in the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.